DOCS Doximitydata gap · 89% coverage
Health Care · Health Care Technology · close $30.97 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Doximity (DOCS) has a ThetaGrade House Rating of 60/100 (grade C), ranking #105 of 150 in Health Care. Its strongest pillars are cash flow (93) and balance sheet (86); its weakest is valuation (35). Data gap: 3 factors without usable data, so 89% of the method weight is covered. TTM revenue growth is 11.2% and operating margin 29.6%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, Interest coverage. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 89% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 46| Revenue growth YoY (TTM) (13.3%) | 11.2% | 56 |
| EPS growth YoY (TTM) (13.3%) | -28.2% | 25 |
| Revenue acceleration (6.7%) | 2.2% | 70 |
Profitability
weight 18.5% (→20.0%) · 52| Operating margin (10.7%) | 29.6% | 86 |
| 4Q gross-margin change (9.3%) | -2.1% | 14 |
Balance sheet
weight 18.5% (→20.0%) · 86| Net debt / EBITDA (13.3%) | -1.31× | 87 |
| Current ratio (6.7%) | 6.08 | 83 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 93| FCF margin (6.7%) | 50.6% | 99 |
| FCF yield (6.7%) | 5.9% | 86 |
Valuation
weight 12.33% (→13.3%) · 35| P/E (inverted) (6.7%) | 36.87× | 37 |
| EV/Sales (inverted) (6.7%) | 8.08× | 33 |
Technicals (EOD)
| RSI(14) | 66.2 |
| EMA 9 / 21 | 30.02 / 28.68 |
| 200-day SMA | 26.08 |
| Volume vs 20d avg | 1.08× |
| 20-day return | 16.6% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (us-gaap CommonStockSharesOutstanding (balance sheet)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like DOCS's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is DOCS's House Rating?
- DOCS scores 60 out of 100 (grade C) as of 2026-10-16, ranking #105 of 150 Health Care stocks we cover.
- What do analysts say about DOCS?
- We do not have enough analyst-sentiment data to score this stock.
- When does DOCS report earnings next?
- DOCS's next earnings report is estimated for about 2026-11-05 (window 2026-11-02 to 2026-11-08), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is DOCS a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology